Literature DB >> 9649646

Bone metabolism in orthotopic liver transplantation: a prospective study.

A Floreani1, W Fries, G Luisetto, P Burra, S Fagiuoli, P Boccagni, G R Della Rovere, M Plebani, A Piccoli, R Naccarato.   

Abstract

Bone mineral density (BMD) and mineral metabolism were assessed in 54 patients with end-stage liver disease who were evaluated for orthotopic liver transplantation (OLT) and assessed 3, 6, and 12 months after surgery in 26 patients who underwent OLT. Serum and urinary electrolyte and mineral levels, serum liver function test results, and parathyroid hormone (PTH), osteocalcin (BGP), 25-hydroxyvitamin D, and urinary hydroxyproline levels were assessed. BMD of the lumbar spine was measured at baseline and 3, 6, and 12 months after OLT. At baseline, 40.7% of patients had BMD below the fracture threshold (0.800 g/cm2). Using multiple stepwise regression analysis, we found that BMD was significantly (P < .0001) affected by age, serum creatinine level, and PTH level but not by indices of cholestasis or liver function. In the patients who underwent OLT, a 1.4% reduction (P < .006) was observed in BMD 3 months after OLT. Thereafter, BMD returned to pretransplant values. A significant increase in serum BGP was observed after 6 (P < .02) and 12 (P < . 005) months. PTH levels increased progressively 3 (P < .02), 6 (P < . 001), and 12 (P < .0001) months after OLT. This increase did not seem to be caused by cyclosporine-induced nephropathy. It was concluded that osteopenia is a major complication in hepatic cirrhosis, regardless of its causes. The increase in serum BGP levels 6 and 12 months after OLT indicates metabolic activation of osteoblasts. The increase in PTH levels after OLT warrants further investigation. Copyright 1998 W.B. Saunders Company.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9649646     DOI: 10.1002/lt.500040413

Source DB:  PubMed          Journal:  Liver Transpl Surg        ISSN: 1074-3022


  7 in total

1.  Osteoporosis is not a specific complication of primary biliary cirrhosis (PBC).

Authors:  A Floreani
Journal:  Gut       Date:  2002-06       Impact factor: 23.059

2.  Pamidronate and osteoporosis prevention in liver transplant recipients.

Authors:  Pietra Pennisi; Andrea Trombetti; Emiliano Giostra; Gilles Mentha; René Rizzoli; Carmelo E Fiore
Journal:  Rheumatol Int       Date:  2006-08-31       Impact factor: 2.631

Review 3.  Hepatic osteodystrophy.

Authors:  Angelo Gatta; Alberto Verardo; Marco Di Pascoli; Sandro Giannini; Massimo Bolognesi
Journal:  Clin Cases Miner Bone Metab       Date:  2014-09

4.  Is osteoporosis a peculiar association with primary biliary cirrhosis?

Authors:  Annarosa Floreani; Andrea Mega; Valentina Camozzi; Vincenzo Baldo; Mario Plebani; Patrizia Burra; Giovanni Luisetto
Journal:  World J Gastroenterol       Date:  2005-09-14       Impact factor: 5.742

5.  Fracture incidence after liver transplantation: results of a 10-year audit.

Authors:  M O Premaor; T K Das; I Debiram; R A Parker; M Ninkovic; G T Alexander; J E Compston
Journal:  QJM       Date:  2011-03-08

Review 6.  Osteoporosis in children and adolescents: etiology and management.

Authors:  Giampiero Igli Baroncelli; Silvano Bertelloni; Federica Sodini; Giuseppe Saggese
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

7.  Primary biliary cirrhosis and osteoporosis: a case-control study.

Authors:  Aziza Mounach; Zhor Ouzzif; Ghizlane Wariaghli; Lahsen Achemlal; Imane Benbaghdadi; Aziz Aouragh; Ahmed Bezza; Abdellah El Maghraoui
Journal:  J Bone Miner Metab       Date:  2008-07-04       Impact factor: 2.626

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.